AmerisourceBergen Approves Quarterly Dividend

  AmerisourceBergen Approves Quarterly Dividend

Business Wire

VALLEY FORGE, Pa. -- May 6, 2013

The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC) today
declared a cash dividend of $0.21 per share on Common Stock, payable June 3,
2013, to stockholders of record at the close of business on May 20, 2013.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in the
pharmaceutical supply channel, the Company provides drug distribution and
related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from niche premium logistics and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With over $80 billion in annualized revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 13,000 people.
AmerisourceBergen is ranked #32 on the Fortune 500 list. For more information,
go to

Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Words such as
“expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,”
“will,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy,” “on
track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” ”possible,”
“assume,” variations of such words and similar expressions are intended to
identify such forward-looking statements. These statements are based on
management's current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance, are
based on assumptions that could prove incorrect or could cause actual results
to vary materially from those indicated. Among the factors that could cause
actual results to differ materially from those projected, anticipated or
implied are the following: changes in pharmaceutical market growth rates; the
loss of one or more key customer or supplier relationships; changes in
customer mix; customer delinquencies, defaults or insolvencies; supplier
defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract or
other dispute with customers or suppliers; federal and state government
enforcement initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; qui tam litigation for
alleged violations of fraud and abuse laws and regulations and/or any other
laws and regulations governing the marketing, sale, purchase, and/or
dispensing of pharmaceutical products or services and any related litigation,
including shareholder derivative lawsuits; changes in federal and state
legislation or regulatory action affecting pharmaceutical product pricing or
reimbursement policies, including under Medicaid and Medicare; changes in
regulatory or clinical medical guidelines and/or labeling for the
pharmaceutical products we distribute, including certain anemia products;
price inflation in branded pharmaceuticals and price deflation in generics;
greater or less than anticipated benefit from launches of the generic versions
of previously patented pharmaceutical products; significant breakdown or
interruption of our information technology systems; our inability to realize
the anticipated benefits of the implementation of an enterprise resource
planning (ERP) system; interest rate and foreign currency exchange rate
fluctuations; risks associated with international business operations,
including non-compliance with the U.S. Foreign Corrupt Practices Act,
anti-bribery laws and economic sanctions and import laws and regulations;
economic, business, competitive and/or regulatory developments outside of the
United States; risks associated with the strategic, long-term relationship
among Walgreen Co., Alliance Boots GmbH, and AmerisourceBergen, including the
failure to obtain the required U.S. and foreign antitrust regulatory approvals
for the equity investments by Walgreens and Alliance Boots in
AmerisourceBergen, the occurrence of any event, change or other circumstance
that could give rise to the termination, cross-termination or modification of
any of the transaction documents among the parties (including, among others,
the distribution agreement or the generics agreement), an impact on our
earnings per share resulting from the issuance of the warrants, an inability
to realize anticipated benefits (including benefits resulting from
participation in the Walgreens Boots Alliance Development GmbH joint venture),
the disruption of AmerisourceBergen’s cash flow and ability to return value to
its stockholders in accordance with its past practices, disruption of or
changes in vendor, payer and customer relationships and terms, and the
reduction of AmerisourceBergen’s operational, strategic or financial
flexibility; the acquisition of businesses that do not perform as we expect or
that are difficult for us to integrate or control; our inability to
successfully complete any other transaction that we may wish to pursue from
time to time; changes in tax laws or legislative initiatives that could
adversely affect our tax positions and/or our tax liabilities or adverse
resolution of challenges to our tax positions; increased costs of maintaining,
or reductions in our ability to maintain, adequate liquidity and financing
sources; volatility and deterioration of the capital and credit markets; and
other economic, business, competitive, legal, tax, regulatory and/or
operational factors affecting our business generally. Certain additional
factors that management believes could cause actual outcomes and results to
differ materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on Form
10-K for the fiscal year ended September 30, 2012 and elsewhere in that report
and (ii) in other reports filed by the Company pursuant to the Securities
Exchange Act of 1934. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
Except to the extent required by law, AmerisourceBergen does not undertake,
and expressly disclaims, any duty or obligation to publicly update any
forward-looking statement after the date of this report, whether as a result
of new information, future events, changes in assumptions or otherwise.


AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199
Press spacebar to pause and continue. Press esc to stop.